Larimar Therapeutics, Inc.
LRMRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 5, 2026 | Wedbush | $11.00(+160%) | $4.23 | TheFly | |
| Jun 30, 2026 | Robert W. Baird | Christopher Chen | $5.00(+56%) | $3.20 | TheFly |
| Mar 3, 2026 | Wedbush | Laura Chico | $12.00(+119%) | $5.47 | StreetInsider |
| Sep 30, 2025 | Robert W. Baird | Joel Beatty | $7.00(+107%) | $3.38 | TheFly |
| Dec 17, 2024 | H.C. Wainwright | Edward White | $15.00(+250%) | $4.28 | StreetInsider |
| Oct 30, 2024 | Citigroup | Samantha Semenkow | $14.00(+65%) | $8.46 | StreetInsider |
| Oct 3, 2024 | Wedbush | Laura Chico | $22.00(+250%) | $6.29 | TheFly |
| Apr 3, 2024 | Leerink Partners | Joori Park | $25.00(+230%) | $7.57 | TheFly |
| Dec 13, 2022 | Citigroup | $4.00(+1%) | $3.97 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Outperform | Aug 5, 2026 |
| Baird | maintain | Outperform | Jun 30, 2026 |
| Wedbush | maintain | Outperform | May 18, 2026 |
| Wedbush | maintain | Outperform | Mar 20, 2026 |
| Wedbush | maintain | Outperform | Mar 3, 2026 |
| Wedbush | maintain | Outperform | Feb 25, 2026 |
| Citigroup | maintain | Buy | Feb 25, 2026 |
| Oppenheimer | maintain | Outperform | Oct 2, 2025 |
| Wedbush | maintain | Outperform | Sep 30, 2025 |
| Baird | maintain | Outperform | Sep 30, 2025 |
| JMP Securities | maintain | Market Outperform | Aug 19, 2025 |
| JMP Securities | maintain | Market Outperform | Aug 15, 2025 |
| Guggenheim | maintain | Buy | Jun 25, 2025 |
| Guggenheim | maintain | Buy | Jun 24, 2025 |
| Wedbush | maintain | Outperform | Jun 24, 2025 |
| Guggenheim | maintain | Buy | Mar 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2025 |
| Baird | maintain | Outperform | Mar 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 31, 2024 |
| JMP Securities | maintain | Market Outperform | May 31, 2024 |
| Citigroup | maintain | Buy | May 22, 2024 |
Earnings History
Next report: Mar 19, 2027 · EPS est. $-0.38| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 4, 2026 | $-0.30 | $-0.38 | — | — |
| May 14, 2026 | $-0.31 | $-0.53 | — | — |
| Mar 19, 2026 | $-0.73 | $-0.44 | — | — |
| Nov 5, 2025 | $-0.61 | $-0.39 | — | — |
| Aug 14, 2025 | $-0.41 | $-0.47 | — | — |
| Apr 30, 2025 | $-0.46 | $-0.42 | — | — |
| Mar 24, 2025 | $-0.45 | $-0.29 | $241.0K | — |
| Oct 30, 2024 | $-0.24 | $-0.37 | — | — |
News
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich's ataxia (FA) will be presented as part of three poster present…
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026.
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar's Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development ex…
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
BlackRock Inc. purchased a new stake in Larimar Therapeutics, Inc. (NASDAQ: LRMR) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,678,035 shares of the company's stock, valued at approximately $17,318,000. BlackRock Inc. owned 5.47% of Larimar Therapeutics as of its
Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and three have issued a strong buy recommendation
Dimensional Fund Advisors LP lifted its position in shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR) by 143.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 798,462 shares of the company's stock after buying an additional 470,968 shares during